NA
MRSN

NewEdge Advisors’s Mersana Therapeutics MRSN Stock Holding History

NewEdge Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20
Closed -$1.65K – 3585
2023
Q2 		$1.65K Hold
20
– – ﹤0.01% 3150
2023
Q1 		$2.06K Hold
20
– – ﹤0.01% 3024
2022
Q4 		$3 Buy
+20
New +$3.38K ﹤0.01% 3905

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

NewEdge Advisors's MRSN Position: Q3 2023 in Review

NewEdge Advisors sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 20 shares — an estimated $1.65K sold.

NewEdge Advisors first reported a position in MRSN in Q4 2022 and held it in 3 quarters. The position peaked at $2.06K in Q1 2023. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • NewEdge Advisors reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewEdge Advisors sold 20 Mersana Therapeutics shares in Q3 2023, an estimated $1.65K.
  • NewEdge Advisors first reported a position in Mersana Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewEdge Advisors's Mersana Therapeutics position peaked at $2.06K in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.